Purchase this article with an account.
Juan Pablo Salica, Eduardo Chuluyan, Diego Guerrieri, Gustavo Ortiz, Juan E Gallo; Antiinflammatory and antiangiogenic effect of a novel Fusion Protein “SLPI and Cementoin” targeting NF-κB pathway. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4725.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We have previously demonstrated the anti-inflammatory and antiangiogentic effect of the fusion protein (SLPI and Cementoin) on a rat corneal alkali injury model. In this study we aimed at evaluating the effect of the fusion protein on the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway during the acute inflammation process on a rat corneal alkali injury model.
An alkali injury was produced with a filter paper of 3 mm with 1 N NaOH during 40 seconds in the right cornea of 27 Sprague-Dowley rats under general anesthesia. They were treated with FP-MC (0,2 ug/ul; n=9), SLPI (0,2 ug/ul; n=9) or vehicle (10ul; n=9) topically, four times a day. Three rats of each group were sacrificed at 6 hours, 4 days and 10 days after injury. Corneas were processed for Western Blot analysis and primary antibodies against the canonical and non canonical NF-kB pathway were used.
We found that the alkali injury-induced phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) and nuclear translocation of p65 were impaired by the fusion protein in comparison to the SLPI and Buffer treatment.
The fusion protein keeps the property of its constituent serpin, showing an inhibition of the NF-kB pathway. Targeting NF-kB pathway is one of the proven mechanisms of action of this novel protein with anti-inflammatory and antiangiogentic effect.
This PDF is available to Subscribers Only